FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898440340> ?p ?o ?g. }

• W2898440340 endingPage "viii508" @default.
• W2898440340 startingPage "viii508" @default.
• W2898440340 abstract "Background: Baseline dNLR is associated with ICI outcomes in advanced NSCLC; we previously reported that the early dNLR change during ICI was correlated to benefit in 292 advanced NSCLC patients. We aimed to confirm the impact of dNLR monitoring in a larger cohort. Methods: 1225 patients with advanced NSCLC treated with ICI (PD1/PDL1 +/- CTLA4) from 10 European/US centers were identified between Nov. 2012 and Mar. 2018. dNLR at baseline and before cycle 2 were retrospectively collected. dNLR was defined as neutrophils/(leucocytes-neutrophils). dNLR monitoring, combining dNLR at baseline (B) et before cycle 2 (C2) stratified the 3 groups: good (if dNLR≤3 remained low at B and C2), intermediate (if dNLR status increased ≤3 at B and >3 at C2 or decreased >3 at B and ≤3 at C2), poor (dNLR>3 at B and C2). Results: 689 (56%) were males, 1058 (87%) smokers, 1066 (87%) with PS ≤ 1, with median age 65 years; 926 (76%) had nonsquamous; 108 were KRASm. PDL1 was known in 403/1225 (33%) and was ≥1% in 270 (67%). The median PFS and OS were 3.1m [95% CI 3-4] and 12m [10-13.7]. dNLR was >3 at B in 416 (34%) and before C2 in 417 pts (34%). At C2, the dNLR status changed in 267 pts, with 133 (11%) dNLR decreased and 134 (11%) dNLR increased. The median OS was 18.6m [16-21] for the good group when dNLR remained low (n = 675, 55%), 9.2m [8-13.9] for the intermediate when dNLR changed (n = 267, 22%) and 5m [4-6.3] for the poor group when dNLR remained high (dNLR>3, n = 283, 23%) (P < 0.0001). The median PFS was 5m [4-5.5] for the good group, 2.6m [2-4] for the intermediate and 2m [2-2.6] for the poor group (P < 0.0001). The poor group was associated with radiological disease progression (OR 2.22, CI 1.33-3.7, P = 0.002). Conclusions: Baseline and 2nd cycle dNLR monitoring can early discriminate the benefit to ICI in advanced NSCLC patients on treatment. dNLR should be prospectively studied in clinical trials. Legal entity responsible for the study: Benjamin Besse. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.Table: 1407PMultivariate analysisProgression-free Survival (PFS)Overall Survival (OS)HR95% CIP valueHR95% CIP valueAge >65 years0.980.79-1.210.8471.150.89-1.470.292Gender Male0.920.72-1.180.5251.050.79-1.410.712Smoking Former/current smoker0.560.38-0.840.0050.490.49-1.230.294Histology Squamous1.250.98-1.600.201.330.99-1.780.16N# line of ICI >20.880.70-1.090.2320.930.72-1.200.581N# metastatic sites >21.561.26-1.94<0.00011.701.31-2.2<0.0001Performance status ≥21.73.29-2.31<0.00012.051.49-2.82<0.0001dNLR monitoring Intermediate Poor1.24 1.620.94-1.62 1.22-2.130.0031.23 2.340.89-1.70 1.72-3.18<0.0001 Open table in a new tab" @default.
• W2898440340 created "2018-11-02" @default.
• W2898440340 creator A5001147279 @default.
• W2898440340 creator A5002771445 @default.
• W2898440340 creator A5002994604 @default.
• W2898440340 creator A5005948108 @default.
• W2898440340 creator A5009978511 @default.
• W2898440340 creator A5013585698 @default.
• W2898440340 creator A5015379222 @default.
• W2898440340 creator A5023794502 @default.
• W2898440340 creator A5028596081 @default.
• W2898440340 creator A5029805571 @default.
• W2898440340 creator A5035197776 @default.
• W2898440340 creator A5038686648 @default.
• W2898440340 creator A5039995907 @default.
• W2898440340 creator A5047053195 @default.
• W2898440340 creator A5059355812 @default.
• W2898440340 creator A5063070072 @default.
• W2898440340 creator A5063103135 @default.
• W2898440340 creator A5068401391 @default.
• W2898440340 creator A5075642945 @default.
• W2898440340 creator A5079805211 @default.
• W2898440340 date "2018-10-01" @default.
• W2898440340 modified "2023-09-27" @default.
• W2898440340 title "Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients" @default.
• W2898440340 doi "https://doi.org/10.1093/annonc/mdy292.029" @default.
• W2898440340 hasPublicationYear "2018" @default.
• W2898440340 type Work @default.
• W2898440340 sameAs 2898440340 @default.
• W2898440340 citedByCount "2" @default.
• W2898440340 countsByYear W28984403402020 @default.
• W2898440340 crossrefType "journal-article" @default.
• W2898440340 hasAuthorship W2898440340A5001147279 @default.
• W2898440340 hasAuthorship W2898440340A5002771445 @default.
• W2898440340 hasAuthorship W2898440340A5002994604 @default.
• W2898440340 hasAuthorship W2898440340A5005948108 @default.
• W2898440340 hasAuthorship W2898440340A5009978511 @default.
• W2898440340 hasAuthorship W2898440340A5013585698 @default.
• W2898440340 hasAuthorship W2898440340A5015379222 @default.
• W2898440340 hasAuthorship W2898440340A5023794502 @default.
• W2898440340 hasAuthorship W2898440340A5028596081 @default.
• W2898440340 hasAuthorship W2898440340A5029805571 @default.
• W2898440340 hasAuthorship W2898440340A5035197776 @default.
• W2898440340 hasAuthorship W2898440340A5038686648 @default.
• W2898440340 hasAuthorship W2898440340A5039995907 @default.
• W2898440340 hasAuthorship W2898440340A5047053195 @default.
• W2898440340 hasAuthorship W2898440340A5059355812 @default.
• W2898440340 hasAuthorship W2898440340A5063070072 @default.
• W2898440340 hasAuthorship W2898440340A5063103135 @default.
• W2898440340 hasAuthorship W2898440340A5068401391 @default.
• W2898440340 hasAuthorship W2898440340A5075642945 @default.
• W2898440340 hasAuthorship W2898440340A5079805211 @default.
• W2898440340 hasBestOaLocation W28984403401 @default.
• W2898440340 hasConcept C126322002 @default.
• W2898440340 hasConcept C167135981 @default.
• W2898440340 hasConcept C2776256026 @default.
• W2898440340 hasConcept C71924100 @default.
• W2898440340 hasConcept C90924648 @default.
• W2898440340 hasConceptScore W2898440340C126322002 @default.
• W2898440340 hasConceptScore W2898440340C167135981 @default.
• W2898440340 hasConceptScore W2898440340C2776256026 @default.
• W2898440340 hasConceptScore W2898440340C71924100 @default.
• W2898440340 hasConceptScore W2898440340C90924648 @default.
• W2898440340 hasLocation W28984403401 @default.
• W2898440340 hasLocation W28984403402 @default.
• W2898440340 hasOpenAccess W2898440340 @default.
• W2898440340 hasPrimaryLocation W28984403401 @default.
• W2898440340 hasRelatedWork W1967103478 @default.
• W2898440340 hasRelatedWork W2032912323 @default.
• W2898440340 hasRelatedWork W2148097028 @default.
• W2898440340 hasRelatedWork W2365632055 @default.
• W2898440340 hasRelatedWork W2372561159 @default.
• W2898440340 hasRelatedWork W2375344515 @default.
• W2898440340 hasRelatedWork W2380382254 @default.
• W2898440340 hasRelatedWork W2390152934 @default.
• W2898440340 hasRelatedWork W2412727163 @default.
• W2898440340 hasRelatedWork W4367672288 @default.
• W2898440340 hasVolume "29" @default.
• W2898440340 isParatext "false" @default.
• W2898440340 isRetracted "false" @default.
• W2898440340 magId "2898440340" @default.
• W2898440340 workType "article" @default.